Human Investing LLC Sells 46 Shares of Amgen Inc. (NASDAQ:AMGN)

Human Investing LLC lowered its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 1.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,702 shares of the medical research company’s stock after selling 46 shares during the quarter. Human Investing LLC’s holdings in Amgen were worth $1,515,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in AMGN. Private Advisor Group LLC increased its position in Amgen by 4.1% in the first quarter. Private Advisor Group LLC now owns 51,429 shares of the medical research company’s stock worth $14,622,000 after purchasing an additional 2,010 shares during the last quarter. Janney Montgomery Scott LLC raised its holdings in shares of Amgen by 7.5% in the 1st quarter. Janney Montgomery Scott LLC now owns 313,781 shares of the medical research company’s stock valued at $89,214,000 after purchasing an additional 21,824 shares in the last quarter. KFA Private Wealth Group LLC raised its stake in Amgen by 22.7% in the first quarter. KFA Private Wealth Group LLC now owns 1,752 shares of the medical research company’s stock worth $498,000 after buying an additional 324 shares in the last quarter. Connecticut Wealth Management LLC lifted its stake in shares of Amgen by 2.1% during the 1st quarter. Connecticut Wealth Management LLC now owns 2,107 shares of the medical research company’s stock worth $599,000 after purchasing an additional 43 shares during the last quarter. Finally, Resonant Capital Advisors LLC lifted its position in shares of Amgen by 0.6% during the first quarter. Resonant Capital Advisors LLC now owns 11,646 shares of the medical research company’s stock valued at $3,311,000 after buying an additional 73 shares during the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

Amgen Trading Down 0.0 %

Amgen stock traded down $0.06 during midday trading on Friday, hitting $320.10. 275,688 shares of the stock were exchanged, compared to its average volume of 2,410,774. The company has a current ratio of 1.26, a quick ratio of 0.89 and a debt-to-equity ratio of 9.64. The stock has a market capitalization of $172.00 billion, a price-to-earnings ratio of 40.99, a PEG ratio of 2.84 and a beta of 0.61. The stock’s 50-day simple moving average is $324.66 and its 200 day simple moving average is $314.82. Amgen Inc. has a fifty-two week low of $260.52 and a fifty-two week high of $346.85.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, beating the consensus estimate of $5.11 by $0.47. The business had revenue of $8.50 billion for the quarter, compared to analyst estimates of $8.50 billion. Amgen had a return on equity of 181.58% and a net margin of 13.00%. The company’s quarterly revenue was up 23.2% on a year-over-year basis. During the same quarter in the prior year, the company posted $4.96 EPS. On average, equities analysts anticipate that Amgen Inc. will post 19.48 EPS for the current year.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, December 9th. Stockholders of record on Monday, November 18th will be given a dividend of $2.25 per share. The ex-dividend date of this dividend is Monday, November 18th. This represents a $9.00 annualized dividend and a dividend yield of 2.81%. Amgen’s dividend payout ratio is currently 115.24%.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on AMGN shares. Jefferies Financial Group reissued a “buy” rating and issued a $380.00 price objective (up previously from $375.00) on shares of Amgen in a research report on Wednesday, August 7th. Wells Fargo & Company lowered shares of Amgen from an “overweight” rating to an “equal weight” rating and increased their price objective for the stock from $320.00 to $335.00 in a research note on Wednesday, August 7th. TD Cowen raised their target price on Amgen from $381.00 to $383.00 and gave the stock a “buy” rating in a report on Monday, October 21st. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $362.00 price objective on shares of Amgen in a report on Thursday, September 26th. Finally, Barclays upped their target price on Amgen from $300.00 to $315.00 and gave the stock an “equal weight” rating in a research note on Monday, October 7th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $333.50.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.